AVATAXHER: An open-label, randomized, multicenter study investigating the addition of bevacizumab (B) to neoadjuvant trastuzumab (T) plus docetaxel (D) in patients with early stage HER2-positive breast cancer (HER2+ BC) stratified according to PET change after one therapy cycle.
Bruno P. Coudert
Consultant or Advisory Role - Genomic Health; Pfizer; Roche
Honoraria - Amgen; Roche
Other Remuneration - GlaxoSmithKline; Lilly; Roche
Jean-Yves Pierga
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
Research Funding - Roche
Marie-Ange Mouret-Reynier
No relevant relationships to disclose
Khaldoun Kerrou
Research Funding - Roche
Jean-Marc Ferrero
No relevant relationships to disclose
Thierry Petit
Consultant or Advisory Role - Roche
Honoraria - Roche
Pierre Kerbrat
No relevant relationships to disclose
Pierre-Francois Dupre
No relevant relationships to disclose
Thomas Denis Bachelot
Consultant or Advisory Role - Roche
Research Funding - Roche
Philippe Gabelle
No relevant relationships to disclose
Sylvia Giard
Consultant or Advisory Role - Roche (U)
Expert Testimony - Surgery (U)
David Coeffic
Honoraria - Roche
Philippe Bougnoux
No relevant relationships to disclose
Jean Briac Prevost
No relevant relationships to disclose
Gilles Paintaud
Research Funding - Roche
Gilles Thibault
Research Funding - Roche
Juana Hernandez
Employment or Leadership Position - Roche
Mathieu Coudert
Employment or Leadership Position - Roche
Laurent Arnould
Consultant or Advisory Role - Roche
Honoraria - Roche
Other Remuneration - Roche
Alina Berriolo-Riedinger
No relevant relationships to disclose